Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma

October 30, 2020 | Comments Off on Targeting and Efficacy of Novel mAb806-Antibody-Drug Conjugates in Malignant Mesothelioma

Pharmaceuticals 2020 October 2 [Link] Puey-Ling Chia, Sagun Parakh, Ming-Sound Tsao, Nhu-An Pham, Hui K Gan, Diana Cao, Ingrid J G Burvenich, Angela Rigopoulos, Edward B Reilly, Thomas John, Andrew…

The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma

October 29, 2020 | Comments Off on The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma

Cytopathology 2020 October 6 [Link] Ben Davidson, Annika Jøntvedt Bock, Arild Holth, Dag Andre Nymoen Abstract Objective: To analyze the expression and clinical role of the phosphatase PTPN1 (PTP1B) in…

Immunotherapy for mesothelioma: rationale and new approaches

October 28, 2020 | Comments Off on Immunotherapy for mesothelioma: rationale and new approaches

Clinical Advances for Hematology and Oncology 2020 September [Link] Joshua E Reuss, Patrick M Forde Abstract Therapeutic advancement for mesothelioma has been stagnant, with minimal treatment innovation in the past…

Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy

October 27, 2020 | Comments Off on Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy

Proc Natl Acad Sci U S A 2020 October 13 [Link] Jiaming Xue, Simone Patergnani, Carlotta Giorgi, Joelle Suarez, Keisuke Goto, Angela Bononi, Mika Tanji, Flavia Novelli, Sandra Pastorino, Ronghui…

Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis

October 26, 2020 | Comments Off on Selection of microRNAs in extracellular vesicles for diagnosis of malignant pleural mesothelioma by in vitro analysis

Oncology Reports 2020 November [Link] Takanobu Jotatsu, Hiroto Izumi, Yasuo Morimoto, Kazuhiro Yatera Abstract Malignant pleural mesothelioma (MPM) is a malignant tumor which is a challenge for diagnosis and is…

AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression

October 16, 2020 | Comments Off on AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 Expression

Cancers 2020 September 25 [Link] Wei Song, Hao Wang, Minmin Lu, Xinxin Ni, Nacef Bahri, Shuihao Zhu, Limin Chen, Yuehong Wu, Jieqiong Qiu, Jonathan A Fletcher, Wen-Bin Ou Abstract Malignant…

A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

October 15, 2020 | Comments Off on A multicentre randomised phase III trial comparing pembrolizumab vs single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial

Annals of Oncology 2020 September 22 [Link] S Popat, A Curioni-Fontecedro, U Dafni, R Shah, M O’Brien, A Pope, P Fisher, J Spicer, A Roy, D Gilligan, O Gautschi, E…

Foxp3 + Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma

October 14, 2020 | Comments Off on Foxp3 + Regulatory T Cell Depletion after Nonablative Oligofractionated Irradiation Boosts the Abscopal Effects in Murine Malignant Mesothelioma

Journal of Immunology 2020 September 18 [Link] Mikihiro Kohno, Junichi Murakami, Licun Wu, Mei-Lin Chan, Zhihong Yun, B C John Cho, Marc de Perrot Abstract Increasing evidence indicates that local…

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

October 9, 2020 | Comments Off on Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

The Lancet Oncology 2020 October [Link] Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller…

Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report)

October 8, 2020 | Comments Off on Tissue expression of lactate transporters (MCT1 and MCT4) and prognosis of malignant pleural mesothelioma (brief report)

Journal of Translational Medicine 2020 September 4 [Link] Irene Dell’Anno, Elisa Barone, Luciano Mutti, Doris M Rassl, Stefan J Marciniak, Roberto Silvestri, Stefano Landi, Federica Gemignani Abstract Background: Malignant pleural…

Categories